295
Participants
Start Date
January 23, 2017
Primary Completion Date
November 27, 2018
Study Completion Date
November 27, 2018
Patiromer
2 packets/day starting dose, administered orally
Placebo
2 packets/day starting dose, administered orally
Spironolactone
25 mg tablet/day starting dose, administered orally
Investigator Site 1402, Sofia
Investigator Site 4611, Debrecen
Investiagor Site 2205, Zagreb
Investigator Site 2201, Zagreb
Investigator Site 2202, Zagreb
Investigator Site 2203, Zagreb
Investigator Site 1023, Miami Lakes
Investigator Site 1012, Hollywood
Investigator Site 4202, Göttingen
Investigator Site 1022, Chicago
Investiagor Site 7809, Kharkiv
Investigator Site 7803, Kharkiv
Investigator Site 7808, Kharkiv
Investigator Site 7802, Kharkiv
Investigator Site 7804, Zaporizhzhia
Investigator Site 7807, Zaporizhzhia
Investigator Site 3806, Tbilisi
Investigator Site 3811, Tbilisi
Investigator Site 3802, Tbilisi
Investigator Site 3801, Tbilisi
Investigator Site 3804, Tbilisi
Investigator Site 3805, Tbilisi
Investigator Site 3807, Tbilisi
Investigator Site 3808, Tbilisi
Investigator Site 3810, Tbilisi
Investigator Site 3812, Tbilisi
Investigator Site 3813, Tbilisi
Investigator Site 3809, Tbilisi
Investigator Site 4607, Balatonfüred
Investigator Site 4606, Budapest
Investigator Site 4601, Hatvan
Investigator Site 4605, Kistarcsa
Investigator Site 4602, Miskolc
Investigator Site 4610, Miskolc
Investigator Site 4608, Mosonmagyaróvár
Investigator Site 7403, Johannesburg
Investigator Site 7805, Kiev
Investigator Site 7801, Kiev
Investigator Site 8202, Leicester
Investigator Site 8205, London
Relypsa, Inc.
INDUSTRY